

FDG-PET/CT as prognostic factor and surveillance tool for postoperative radiation recurrence in locally advanced head and neck cancer

Giwon Kim, MD¹, Yeon Sil Kim, MD¹, Eun Ji Han, MD², Je Ryung Yoo, MD², Jin-Ho Song, MD¹, Sang-Nam Lee, MD¹, Jong Hoon Lee, MD¹, Byung-Oak Choi, MD¹, Hong-Seok Jang, MD¹, Sei-Chul Yoon, MD¹

Departments of ¹Radiation Oncology, ²Radiology, The Catholic University of Korea School of Medicine, Seoul, Korea

Purpose: To evaluate the prognostic value of metabolic tumor volume (MTV) and maximum standardized uptake value (SUVmax) on initial positron emission tomography-computed tomography (PET-CT) and investigate the clinical value of SUVmax for early detection of locoregional recurrent disease after postoperative radiotherapy in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).

Materials and Methods: A total of 100 patients with locally advanced HNSCC received primary tumor excision and neck dissection followed by adjuvant radiotherapy with or without chemotherapy. The MTV and SUVmax were measured from primary sites and neck nodes. The prognostic value of MTV and SUVmax were assessed using initial staging PET/CT (study A). Follow-up PET/CT scan available after postoperative concurrent chemoradiotherapy or radiotherapy were evaluated for the SUVmax value and correlated with locoregional recurrence (study B). A receiver operating characteristic (ROC) curve analysis was used to define a threshold value of SUVmax with the highest accuracy for recurrent disease assessment.

Results: High MTV (>41 mL) is negative prognostic factor for disease free survival ($p = 0.041$). Postradiation SUVmax was significantly correlated with locoregional recurrence (hazard ratio, 1.812; 95% confidence interval, 1.361 to 2.413; $p < 0.001$). A cut-off value of 5.38 from follow-up PET/CT was identified as having maximal accuracy for detecting locoregional recurrence by ROC analysis.

Conclusion: MTV at staging work-up was significantly associated with disease free survival. The SUVmax value from follow-up PET/CT showed high diagnostic accuracy for the detection of locoregional recurrence in postoperatively irradiated HNSCC.

Keywords: Head and neck squamous cell carcinoma, Metabolic tumor volume, Positron-emission tomography, Postoperative radiation therapy, Locoregional recurrence

Introduction

Patients with locoregionally advanced head and neck squa-

mous cell carcinoma (HNSCC) are generally treated with multimodality therapy consisting of surgery, radiotherapy, and chemotherapy. When surgery is the primary treatment

Received 30 August 2011, Revised 30 September 2011, Accepted 17 October 2011.

Correspondence: Yeon Sil Kim, MD, Department of Radiation Oncology, Seoul St. Mary Hospital, The Catholic University of Korea School of Medicine, 505 Banpo-dong, Seocho-gu, Seoul 137-701, Korea. Tel: +82-2-2258-6259, Fax: +82-2-2258-1532, E-mail: yeonkim7@catholic.ac.kr

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

www.e-roj.org

Table 1. Inclusion criteria of study A and B

	Study A	Study B
Purpose of study	Prediction of treatment outcome	Early detection of recurrence
Period	December 2003-April 2009	May 1994-January 2009
Disease	Head and neck cancer	
AJCC stage	III or IV	
Cell type	Squamous cell carcinoma	
Surgery	Primary tumor excision and bilateral or ipsilateral neck dissection	
Adjuvant RT	Radiation therapy with or without chemotherapy	
Status after treatment	Various	No evidence of disease
PET/CT at staging workup	Yes	Yes or No
PET/CT at follow-up	Yes or No	Yes
Number of patients	69	81
Measured value on PET/CT	SUVmax, MTV	SUVmax
Site of measurement	Primary tumor and nodes	Excised tumor bed and nodes

AJCC, American Joint Committee on Cancer; RT, radiotherapy; PET/CT, positron emission tomography/computed tomography; SUVmax, maximal standardized uptake value; MTV, metabolic tumor volume.

for advanced HNSCC, surgery followed by adjuvant chemoradiotherapy is considered as the standard for neck disease with multiple lymph nodes or extracapsular extension or positive surgical margin [1,2]. For patients at high risk of locoregional recurrence, risk assessment and proper surveillance including physical examination and reliable imaging, could potentially improve survival. The prognostic and diagnostic value of positron emission tomography/computed tomography (PET/CT) is increasingly interested in patients with recurrent HNSCC [3-8]. Recent studies show that maximum standardized uptake value (SUVmax) or metabolic tumor volume (MTV) from PET/CT may be useful to predict recurrence in patients with head and neck cancer treated with concurrent chemoradiotherapy [9-12]. PET/CT also has high specificity and sensitivity for detecting recurrent disease. For both definitive concurrent chemoradiotherapy and radical surgery, this suggests possible benefit for the determination of treatment response and for the early detection of recurrence. However, post-treatment changes such as inflammation and fibrosis might result in relatively low positive predictive value for detecting recurrence [7,13,14].

We performed two analyses using PET/CT focused on locoregional recurrence in HNSCC patients treated with surgery followed by adjuvant radiotherapy. First, we investigated the value of MTV and SUVmax at staging workup for predicting recurrence. Second, we examined the diagnostic accuracy of PET/CT in the detection of post-treatment recurrence.

Materials and Methods

1. Inclusion criteria and patient characteristics

This retrospective study was approved by the Institutional Review Board of the Catholic University of Korea. Informed consent was waived due to the retrospective design of the study. Between May 1994 and April 2009, a total of 100 patients with locally advanced HNSCC received primary tumor excision and neck dissection followed by adjuvant radiotherapy with or without chemotherapy. Criteria for patient inclusion into study A or B is showed at Table 1. There was 69 patients in study A who underwent a PET/CT scan as part of staging workup and 81 patients in study B who underwent a PET/CT as follow-up after completion of surgery and adjuvant radiotherapy. Of these, 50 of the 100 total patients underwent PET/CT imaging at both staging workup and follow-up. After completion of treatment, patients who had residual disease by clinical or radiographic evaluation were excluded from study B. The prognostic value of PET/CT on predicting disease free survival was investigated in study A and the clinical value of the early detection of post-treatment locoregional recurrence was evaluated in study B. Demographic and clinical characteristics for both study A and B are summarized in Table 2. Patients in both the study A and B had similar characteristics and received similar treatment with the exception of the time of PET/CT imaging and treatment response. Patient characteristics, including age ($p = 0.499$), gender ($p = 0.734$), primary site ($p = 0.569$), American Joint Committee on Cancer

Table 2. Patient characteristics

Characteristics	Study A	Study B
Age (yr)		
Range	26-75	26-79
Median	58	56
Gender		
Male	62 (89.9)	75 (92.6)
Female	7 (10.1)	6 (7.4)
Site		
Oropharynx	15 (21.7)	25 (30.9)
Oral cavity	16 (23.2)	19 (23.5)
Hypopharynx	11 (15.9)	13 (16.0)
Larynx	14 (20.3)	17 (21.0)
Others (nasal cavity, salivary, lacrimal, MUO)	13 (18.8)	7 (8.6)
AJCC stage		
III	16 (22.9)	14 (17.3)
IV	53 (75.7)	67 (82.7)
Smoking (pack/yr)		
None	2 (2.9)	5 (6.2)
<10	6 (8.7)	6 (7.4)
≥10	37 (53.6)	45 (55.5)
N/A	24 (34.8)	25 (30.9)
ECOG performance status		
0-I	49 (71.0)	70 (86.4)
II	18 (26.1)	10 (12.3)
III	2 (2.9)	1 (1.2)
Resection margin		
Negative	16 (23.2)	32 (39.0)
Close (<0.5 cm)	36 (52.2)	30 (36.6)
Positive	10 (14.5)	12 (14.6)
N/A	7 (10.1)	8 (9.8)
ECS		
Negative	28 (40.6)	34 (41.5)
Positive	34 (49.3)	35 (42.7)
N/A	7 (10.1)	13 (15.9)
RT or CCRT		
Postoperative-RT	31 (44.9)	36 (44.4)
Postoperative-CCRT	38 (55.1)	45 (55.6)
Radiation dose		
<60 Gy in 1.8 Gy fractions	28 (40.6)	10 (12.3)
60 Gy in 1.8 Gy fractions	4 (5.8)	32 (39.6)
>60 Gy in 1.8 Gy fractions	37 (53.6)	39 (48.1)

MUO, Malignancy of unknown origin.

(AJCC) stage ($p = 0.653$), performance status ($p = 0.131$) between two studies were not significantly different by chi-square test. The majority of patients were middle-aged males who were heavy smoker with stage IV cancer treated with radical surgery (primary mass excision and bilateral neck

Table 2. Continued

Characteristics	Study A	Study B
Recurrent site		
Locoregional	12/23 (52.2) ^{a)}	8/23 (34.7)
Locoregional + distant	6/23 (26.1)	8/23 (34.7)
Distant	5/23 (22.7) ^{b)}	7/23 (30.6)
Follow-up duration (mo)		
Range	4.1-68	4.1-180.2
Median	29.3	35.4
Total number of patients	69	81

Values are presented as number (%).

MUO, malignancy of unknown origin; AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; N/A, not available; ECS, extracapsular spread; RT, radiotherapy; CCRT, concurrent chemoradiotherapy.

^{a)}Included patients with incomplete response for treatment. ^{b)}Included patients with distant metastasis at the end of treatment.

dissection) with ≥60 Gy adjuvant chemoradiotherapy.

2. Treatments

The primary tumor excision and modified neck dissection were performed and followed by postoperative radiotherapy with or without chemotherapy in all patients. Radiotherapy was scheduled within 8 weeks after surgery. Radiotherapy was delivered via 3-dimensional technique. The prescribed dose was 1.8 to 2 Gy per fraction and given 5 days per week. The total radiation dose was given in 60 Gy (range, 32 to 70 Gy). A boost dose of 5-6 Gy was administered for patients with multiple positive neck nodes, extracapsular spread, and involved margin. Concurrent chemoradiotherapy with a schedule of weekly cisplatin (30 mg/m²) was administered to patients with extracapsular spread, multiple lymph nodes or positive margin [15].

3. Follow-up

Standard head and neck examination was performed in all patients during follow-up at 3-month intervals for the first 2 years and at 6-month intervals thereafter including flexible nasolaryngoscopy. The post-treatment PET/CT scan was recommended at usually 2 to 4 months after the completion of radiotherapy or concurrent chemoradiotherapy and then 6-month interval thereafter.

4. FDG-PET/CT imaging protocol

All patients fasted for at least 6 hours before the PET/CT study.

An amount of 370-555 MBq of F-18 flouorodeoxyglucose (FDG) was injected intravenously, and scanning began 60 minutes later. No intravenous contrast agent was used. Images were acquired on combined PET/CT in-line systems, either Biograph Duo or Biograph Truepoint (Siemens Medical Solutions, Knoxville, TN, USA). The acquisition time was 2 to 3 minutes per each bed position. All patients were in supine position with their arms raised. CT began at the orbitomeatal line and progressed to the upper thigh (130 kVp, 80 mAs, and 5 mm slice thickness; 120 kVp, 50 mAs, and 5 mm slice thickness). PET followed immediately over the same body region. The CT data were used for attenuation correction, and images were reconstructed using a standard ordered-subset expectation maximization (OSEM) algorithm. The axial spatial resolution was 6.5 mm or 4.5 mm at the center of the field of view.

5. Measurement of SUVmax and MTV

All PET/CT images were reviewed at a workstation with fusion software (Syngo; Siemens Medical Solution) that provided multiplanar reformatted images and displayed PET images after attenuation correction, CT images, and PET/CT fusion images. The images were closely searched for increased uptake in head and neck region by one physician who was board certified in both nuclear medicine and radiology. The SUVs were acquired using attenuation-corrected images. In initial PET/CT scans, the SUVmax of primary tumor and metastatic lymphadenopathies was obtained from transaxial views. In follow-up PET/CT scans, SUVmax was obtained from the postoperative tumor bed and dissected neck node. For patients with multiple sites of locoregional recurrence, the highest SUV was selected. The MTV of primary tumor and metastatic lymphadenopathies was measured using an automated contouring program (Siemens Medical Solutions). Of various methods for measurement of metabolic volume, a cut-off of SUV 2.5 was used. The boundaries were drawn large enough to incorporate target lesions in transaxial, coronal and sagittal views. Then isocontour connecting the lesion showing an SUV of 2.5 was set automatically inside the boundary, and all voxels with an SUV of >2.5 within the isocontour were included in MTV calculation [9,16].

6. Post-treatment surveillance and recurrence determination

After completion of postoperative radiotherapy, clinical examination and radiological imaging (CT or magnetic resonance imaging [MRI]) follow-up were performed by above

mentioned interval. All patients in study B had no residual disease and underwent follow-up PET/CT at least once. The median time interval between adjuvant radiotherapy and follow-up PET/CT was 26.7 weeks. Determining locoregional recurrence was confirmed either pathologically or any failure detected by both physical examination with endoscopic evaluation and successive PET/CT or MRI. The first PET/CT data obtained during the period of suspected recurrence was used for patients with the recurrent disease.

7. Statistical analysis

Locoregional disease free survival (LRDFS), disease free survival (DFS) and overall survival (OS) from the date of surgery were estimated using the Kaplan-Meier method. To assess the discriminative power of MTV and SUVmax for predicting DFS, the log-rank test was used and comparison were made at each MTV and SUVmax level in the study A patients. Cox proportional hazards regression was used to determine independent predictors for DFS. SUVmax for patients with or without recurrence were compared using a Student's t-test (significance defined as $p < 0.05$). Logistic regression and receiver operating characteristic (ROC) was performed for PET/CT data of the study B for the highest value in either surgical bed or nodal site. Logistic regression was used in the multivariate analysis and an estimated hazard ratio (HR) with 95% confidence interval (CI) was presented. Polynomial curves were fit to the ROC data and solved for a slope of 1 to identify SUVmax cut-off value with maximum accuracy for detecting recurrence. A cut-off value of SUVmax, identified by the ROC curve, was used to calculate the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of follow-up PET/CT (significance defined as $p < 0.05$). Data were analyzed using SPSS version 12.0 (SPSS Inc., Chicago, IL, USA) in August 2009.

Results

1. Treatment outcomes

The median follow-up time for study A patients was 29.3 months (range, 4.1 to 68 months). Six patients in study A had persistent disease and their disease continued to progress after the completion of treatment. Two patients in study A developed distant metastasis at the end of treatment. The two-year OS rate for study A was 71%, DFS was 63.5%. The median follow-up time for study B patients was 35.4 months (range, 4.1 to 180.2 months). The two-year OS rate for patients in study




Fig. 1. Determination of cut-off values for (A) metabolic tumor volume (MTV) and (B) maximal standardized uptake value (SUVmax) correlated with disease free survival (DFS) in the study A. (A) The most significant cut-off value of MTV was identified at 41 mL (* $p = 0.035$). (B) Any SUVmax value was not statistically significant (p -value was obtained from log-rank test for DFS).

B was 84.8% and locoregional DFS was 83.8%. There were 23 patients with recurrence (crude recurrence rate 28.4%), which occurred at locoregional sites in 8 patients, locoregional and distant sites in 8 patients, and at distant sites in 7 patients. The overall disease control rate for study B was 71.6% and the locoregional control rate was 80.2%.

2. Metabolic tumor volume predicting for disease free survival

We investigated prognostic factors related to recurrence for the patients in study A who underwent PET/CT at initial staging work-up. The median MTV in study A was 24.2 mL (range, 0.1 to 214.9 mL) and the median SUVmax in study A was 10.1 (range, 1.8 to 21.6). We first determined cut-off values of MTV and SUVmax correlating to DFS. Using log-rank test, significant p -values ($p = 0.035$) were obtained from 39 to 43 mL of MTV (Fig. 1A). The median value of MTV, 41 mL was used as the cut-off value for MTV. However, no value for SUVmax was significantly correlated with DFS (Fig. 1B). The lowest p -value ($p = 0.249$) was obtained at 10 of SUVmax. We examined whether MTV, SUVmax, and any patient characteristics were correlated with DFS. Using log-rank test, Eastern Cooperative Oncology Group (ECOG) performance status ($p = 0.0016$), vascular invasion ($p = 0.0062$), extracapsular spread ($p = 0.0019$), and MTV ($p = 0.035$) were significantly associated with DFS. In Cox's proportional hazards analysis, vascular invasion (positive: HR, 6.754; 95% CI, 0.812 to 56.198; $p = 0.077$) and extracapsular spread (positive: HR, 2.594; 95% CI, 0.595 to 11.317; $p = 0.205$) were not significantly correlated with DFS. However,

ECOG performance status remained significant prognostic factors for DFS (HR, 3.553; 95% CI, 1.542 to 8.188; $p = 0.003$). MTV > 41 mL was associated with a 2.4-fold increased risk of recurrence or death (HR, 2.391; 95% CI, 1.037 to 5.511; $p = 0.041$) in advanced HNSCC patients treated with postoperative radiotherapy (Table 3). The two-year DFS for patients with MTV > 41 mL and MTV \leq 41 mL was 48.3% and 70.7%, respectively ($p = 0.035$) (Fig. 2). Conversely, the two-year DFS of patients with SUVmax > 10 was not significantly different when compared with patients with SUVmax \leq 10 (58.9% vs. 68.2%; $p = 0.249$).

3. Correlating post-radiation SUV max with recurrence

Among 31 patients suspected locoregional recurrence, 20 patients underwent pathological evaluation. Finally, sixteen patients (19.8%) confirmed locoregional recurrences in study B either by pathologically or clinically with follow-up imaging studies. Our results showed that SUVmax at staging workup (study A) did not correlate with recurrence. However, post-radiation SUVmax at follow-up was significantly higher in patients with locoregional recurrence compared with non recurrent patients for primary tumor and nodes ($p < 0.001$) (Fig. 3). The mean SUVmax of 65 patients with non recurrent disease was 3.22. The percentage of non-recurrent patients with SUVmax \leq 4.5 was 86.1%. The mean SUVmax of 16 patients with locoregional recurrence was 7.59. Using logistic regression, post-radiation SUVmax was significantly correlated with locoregional recurrence. As the value of SUVmax increased, the probability of locoregional recurrence increased (HR, 1.812; 95% CI, 1.361 to 2.413; $p < 0.001$) (Fig. 4).

Table 3. Analysis of prognostic factors for disease free survival (study A, n = 69). (A) Log rank test

Variables	p-value
Age (yr)	
≤58 vs. > 58	0.3193
Gender	
Male vs. female	0.2010
Smoking (yr)	
≤10 vs. >10	0.9412
ECOG performance status	
0-I vs. II-III	0.0016
AJCC stage	
III vs. IV	0.1407
Resection margin	
Negative vs. close	0.5488
Negative vs. positive	0.0768
Negative vs. close + positive	0.3163
ECS	
Positive vs. negative	0.0019
Histological grade	
WD vs. MD	0.8276
WD vs. PD	0.7291
Vascular invasion	
Positive vs. negative	0.0062
Lymphatic invasion	
Positive vs. negative	0.2112
Perineural invasion	
Positive vs. negative	0.0718
Radiation dose	
≤60 Gy vs. >60 Gy	0.0773
RT vs. CCRT	
Postop RT vs. postop CCRT	0.2419
SUVmax	
≤10 vs. >10	0.2490
MTV	
≤41 vs. >41	0.0350

ECOG, Eastern Cooperative Oncology Group; AJCC, American Joint Committee on Cancer; ECS, extracapsular spread; WD, well differentiated; MD, moderately differentiated; PD, poor differentiated; SUVmax, maximal standardized uptake value; MTV, metabolic tumor volume.

From our results, SUVmax from follow-up PET/CT imaging was significant independent predictor for locoregional recurrence in patients with postoperative radiotherapy with or without chemotherapy.

4. Diagnostic accuracy of follow-up PET/CT for detecting locoregional recurrence

ROC curve analysis was performed on the follow-up PET/CT data to determine the SUVmax values with highest accuracy

Table 3. Continued. (B) Cox's proportional hazards analysis

Variables	HR (95% CI)	p-value
ECOG Performance status	3.553 (1.542-8.188)	0.003
ECS	2.594 (0.595-11.317)	0.205
Vascular invasion	6.754 (0.812-56.198)	0.077
MTV	2.391 (1.037-5.511)	0.041

HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ECS, extracapsular spread; MTV, metabolic tumor volume.




Fig. 2. Disease free survival (DFS) curve according to 41 mL of metabolic tumor value (MTV) in the study A. DFS for patients with MTV ≤ 41 mL was significantly different between those with MTV > 41 mL (p = 0.035).

for postoperative radiotherapy failure (Fig. 5). We identified 5.38 as the cut-off value with maximal accuracy for detecting locoregional recurrence. Using this cut-off value, sensitivity, specificity, PPV, and NPV were calculated. The accuracy of follow-up PET/CT for detecting locoregional recurrence is shown in Table 4. The NPV (93.7%) of follow-up PET/CT was relatively higher than the PPV (66.7%) for the detecting of post-radiation locoregional recurrence.

Discussion and Conclusion

Recent studies have evaluated whether values from initial PET/CT predict treatment outcome in head and neck cancer [9-11,17,18]. Several studies have shown high SUVmax at staging workup predict poor outcome in head and neck cancer [11,17,19]. Despite such findings, our results did not confirm SUVmax as predictor of outcome. Other investigators have also not found any significant correlation SUVmax with treatment outcome in head and neck cancer [9,10,20], whereas MTV




Fig. 3. Maximal standardized uptake value (SUVmax) distribution for recurrent patients and non-recurrent patients (study B). Histogram plots of post-radiation SUVmax value are shown for locoregional site. NED, no evidence of disease.




Fig. 5. Receiver operating characteristic (ROC) curve for post-radiation positron emission tomography/computed tomography is shown (area under ROC curve, 0.901; 95% confidence interval, 0.806-0.996; $p < 0.001$).




Fig. 4. A Binomial logistic regression curve for post-radiation maximal standardized uptake value (SUVmax) value is shown. Locoregional recurrence probability in patients after postoperative adjuvant radiotherapy increases by SUVmax value from follow-up positron emission tomography/computed tomography imaging (hazard ratio, 1.812; 95% confidence interval, 1.361 to 2.413; $p < 0.001$).

from PET/CT has been suggested as prognostic factor in head and neck cancer. La et al. [10] found that high MTV from PET/CT in locally advanced head and cancer correlate with short DFS. Chung et al. [9] also confirmed patient with MTV > 40 mL showed a poor treatment outcome including recurrence by multivariate analysis. To our knowledge, the current study is the first to evaluate MTV as predictor of treatment outcome in HNSCC patients treated with postoperative adjuvant radiotherapy. In our results, patients with MTV >

Table 4. Accuracy of PET-CT detecting locoregional recurrence in patients with postoperative radiotherapy or chemoradiotherapy

Cut-off value of SUVmax	PET-CT	
	5.38	5.99
True positive	12	11
False negative	4	5
True negative	59	60
False positive	6	5
Sensitivity (%)	75	68.8
NPV (%)	93.7	92.3
Specificity (%)	90.8	92.3
PPV (%)	66.7	68.8

A table by cutoff value 5.38 and 5.99 is shown. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated from raw numbers of true and false negative and positive.

PET/CT, positron emission tomography/computed tomography.

41 mL showed short DFS and 2.4-fold higher recurrence or death than patients with MTV \leq 41 mL. Presence of vascular invasion and extracapsular spread also correlated with short DFS by univariate analysis. Because several patients had no information for their vascular invasion and extracapsular spread status, we could not secure sufficient data for multivariate analysis. Prospective and well-controlled study is needed to determine MTV or SUVmax as predictor of outcome in head and neck cancer.

We also evaluated diagnostic accuracy of PET/CT to detect postoperative radiotherapy recurrence focused on primary

site and regional lymph nodes. In the assessment of response and detection of recurrence for head and neck cancer, there are increasing recent data [5-7,12,20]. Moeller et al. [20] showed higher SUVmax in non-responder compared with responder. Our results also showed higher SUVmax at follow-up was significantly associated with locoregional recurrence. From this, we calculated diagnostic accuracy of PET/CT using SUVmax at the first timing of suspected recurrence. Although initial SUVmax may be not predictor of recurrence, this can be objective and useful value for detecting treatment recurrence with cut-off value of 5.38 during post-treatment follow up. We identified NPV as 93.7% and PPV as 66.7% in the postoperative radiotherapy setting. In the recent two studies investigating the performance of PET/CT after concurrent chemoradiotherapy, locoregional NPV and positive PPV from 96.1% to 100% and from 42% to 58.3%, respectively [7,20]. Our cut-off value as 5.38 of locoregional site was lower than the study of Moeller et al. [20] as 6.5 of primary site, moreover showed relatively accurate performance of PET/CT using SUVmax value. Because those used PET/CT data set performed within 12 weeks after treatment, could show relatively lower PPV and higher cut-off value than our results. Timing of PET/CT after treatment was critical for diagnostic accuracy of treatment outcome. Other studies showed that PET/CT performed within 12 weeks after definitive radiotherapy had false positive or false negative case [13,21]. In our study, six non-recurrent patients had persistent higher SUVmax than cut-off value as 5.38 (median SUVmax, 7.1). Primary sites of these were oral cavities (three patients), larynx (two patients) and nasal cavity (one young patient). The median duration of PET/CT in these patients was 52.5 weeks after postoperative radiotherapy. Though none of them undertook PET/CT within less than 8 weeks, they had persistent high SUVmax value. Therefore, our results showed that false positive could be persistent for the long term period in patients treated with postoperative radiotherapy.

Same as recent other studies, the current study had also issue for false positive findings of PET/CT in the post-treatment settings. Diagnostic accuracy of follow-up PET/CT could improve in patients with adverse prognostic factors such as HPV-negative tumors and non-oropharyngeal cancer. In the study of Moeller et al. [20], PPV in the high risk patients as HPV-negative, non-oropharyngeal cancer, and smoking history was 100%. No benefit of PET/CT for low-risk patients suggested need for stratifying patients by risk group in the follow-up. The current study suggested that high MTV could

be a possible prognostic factor of HNSCC patients. In the further prospective study, we can expect more confident PPV in patients with high MTV.

There are several limitations in the current retrospective study. First, more patient accrual needs to increase statistical power. Because routine staging workup did not include PET/CT before 2001, we divided patients into study A and B according to presence of initial PET/CT data set. Only limited number of recurrence in each variant group made insignificant results from multivariate analysis. Second, timing of follow-up PET/CT is another limitation. Although we chose PET/CT data set based on clinicopathological data as physical examination and supportive images, SUVmax value from first suspected recurrence had inherent bias. However, this process may simulate usual clinical practice setting and our result can be usefully applied in appropriate clinical decision. In the current study, we focused on patients treated with excision and neck dissection and measured SUVmax in postoperative tumor bed and dissected neck region. Thus, we did not separate diagnostic accuracy in primary site and lymph nodes in contrast to other investigators [20,22]. Finally, because of the retrospective nature of this study, irregularity of PET/CT follow-up is associated with inherent biases.

In conclusion, results of current study confirm that MTV at staging workup is significantly associated with treatment outcome. At higher than locoregional SUVmax 5.38 from follow-up PET/CT, we can suspect disease recurrence of postoperative irradiated HNSCC. Although high false positive rate in the postoperative irradiated head and neck was noted, follow-up PET/CT was proved to be a useful tool for detecting of locoregional recurrence. We can expect more confident results through further prospective study and comparison with other imaging modalities.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). *Head Neck* 2005;27:843-50.

2. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med* 2004;350:1937-44.
3. Wong RJ, Lin DT, Schoder H, et al. Diagnostic and prognostic value of (18)F-fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. *J Clin Oncol* 2002;20:4199-208.
4. Ong SC, Schoder H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. *J Nucl Med* 2008;49:532-40.
5. Shintani SA, Foote RL, Lowe VJ, Brown PD, Garces YI, Kasperbauer JL. Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. *Int J Radiat Oncol Biol Phys* 2008;70:322-9.
6. Abgral R, Querellou S, Potard G, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? *J Nucl Med* 2009;50:24-9.
7. Kao J, Vu HL, Genden EM, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. *Cancer* 2009;115:4586-94.
8. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. *J Clin Oncol* 2000;18:651-8.
9. Chung MK, Jeong HS, Park SG, et al. Metabolic tumor volume of 18F-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. *Clin Cancer Res* 2009;15:5861-8.
10. La TH, Filion EJ, Turnbull BB, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 2009;74:1335-41.
11. Liao CT, Chang JT, Wang HM, et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. *Int J Radiat Oncol Biol Phys* 2009;73:764-71.
12. Koike I, Ohmura M, Hata M, et al. FDG-PET scanning after radiation can predict tumor regrowth three months later. *Int J Radiat Oncol Biol Phys* 2003;57:1231-8.
13. Andrade RS, Heron DE, Degirmenci B, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. *Int J Radiat Oncol Biol Phys* 2006;65:1315-22.
14. Yao M, Smith RB, Hoffman HT, et al. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. *Int J Radiat Oncol Biol Phys* 2009;74:9-14.
15. Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schweitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. *Int J Radiat Oncol Biol Phys* 1996;36:999-1004.
16. Lee P, Weerasuriya DK, Lavori PW, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. *Int J Radiat Oncol Biol Phys* 2007;69:328-33.
17. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-18F-fluoro-2-deoxy-D-glucose. *Int J Radiat Oncol Biol Phys* 2004;59:1295-300.
18. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. *J Nucl Med* 1997;38:1907-11.
19. Liao CT, Chang JT, Wang HM, et al. Preoperative 18F-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. *Int J Radiat Oncol Biol Phys* 2009;74:1054-61.
20. Moeller BJ, Rana V, Cannon BA, et al. Prospective risk-adjusted 18F-Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. *J Clin Oncol* 2009;27:2509-15.
21. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer. *Head Neck* 2005;27:175-81.
22. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. *Int J Radiat Oncol Biol Phys* 2005;63:991-9.